Literature DB >> 16750270

Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system.

Sandra J Hewett1, Stanley C Bell, James A Hewett.   

Abstract

Cyclooxygenase (COX) enzymes, or prostaglandin-endoperoxide synthases (PTGS), are heme-containing bis-oxygenases that catalyze the first committed reaction in metabolism of arachidonic acid (AA) to the potent lipid mediators, prostanoids and thromboxanes. Two isozymes of COX enzymes (COX-1 and COX-2) have been identified to date. This review will focus specifically on the neurobiological and neuropathological consequences of AA metabolism via the COX-2 pathway and discuss the potential therapeutic benefit of COX-2 inhibition in the setting of neurological disease. However, given the controversy surrounding the use of COX-2 selective inhibitors with respect to cardiovascular health, it will be important to move beyond COX to identify which down-stream effectors are responsible for the deleterious and/or potentially protective effects of COX-2 activation in the setting of neurological disease. Important advances toward this goal are highlighted herein. Identification of unique effectors in AA metabolism could direct the development of new therapeutics holding significant promise for the prevention and treatment of neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750270     DOI: 10.1016/j.pharmthera.2005.04.011

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  34 in total

1.  Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy.

Authors:  Hidetoshi Taniguchi; Christoph Anacker; Gabriela Beatriz Suarez-Mier; Qian Wang; Katrin Andreasson
Journal:  Neurosci Lett       Date:  2011-09-12       Impact factor: 3.046

Review 2.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

Review 3.  Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.

Authors:  Saba Aïd; Francesca Bosetti
Journal:  Biochimie       Date:  2010-09-22       Impact factor: 4.079

Review 4.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest.

Authors:  Hao Liu; Marie E Rose; Tricia M Miller; Wenjin Li; Sunita N Shinde; Alicia M Pickrell; Samuel M Poloyac; Steven H Graham; Robert W Hickey
Journal:  Brain Res       Date:  2013-04-24       Impact factor: 3.252

6.  The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity.

Authors:  Ju Shi; Jenny Johansson; Nathaniel S Woodling; Qian Wang; Thomas J Montine; Katrin Andreasson
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

7.  Prostaglandin signalling in cerebral ischaemia.

Authors:  Katrin Andreasson
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

8.  Divergent effects of prostaglandin receptor signaling on neuronal survival.

Authors:  Liejun Wu; Qian Wang; Xibin Liang; Katrin Andreasson
Journal:  Neurosci Lett       Date:  2007-06-07       Impact factor: 3.046

9.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

10.  Immunohistochemical increase in cyclooxygenase-2 without apoptosis in different brain areas of subchronic nicotine- and D-amphetamine-treated rats.

Authors:  A Toledano; M I Alvarez; I Caballero; P Carmona; E De Miguel
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.